JP2017501205A5 - - Google Patents

Download PDF

Info

Publication number
JP2017501205A5
JP2017501205A5 JP2016544593A JP2016544593A JP2017501205A5 JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5 JP 2016544593 A JP2016544593 A JP 2016544593A JP 2016544593 A JP2016544593 A JP 2016544593A JP 2017501205 A5 JP2017501205 A5 JP 2017501205A5
Authority
JP
Japan
Prior art keywords
alkyl
halo
alkoxy
carbocyclyl
alkanoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016544593A
Other languages
English (en)
Japanese (ja)
Other versions
JP6759100B2 (ja
JP2017501205A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072851 external-priority patent/WO2015103317A1/en
Publication of JP2017501205A publication Critical patent/JP2017501205A/ja
Publication of JP2017501205A5 publication Critical patent/JP2017501205A5/ja
Application granted granted Critical
Publication of JP6759100B2 publication Critical patent/JP6759100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016544593A 2013-12-30 2014-12-30 治療用阻害化合物 Expired - Fee Related JP6759100B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921995P 2013-12-30 2013-12-30
US61/921,995 2013-12-30
US201462025203P 2014-07-16 2014-07-16
US62/025,203 2014-07-16
PCT/US2014/072851 WO2015103317A1 (en) 2013-12-30 2014-12-30 Therapeutic inhibitory compounds

Publications (3)

Publication Number Publication Date
JP2017501205A JP2017501205A (ja) 2017-01-12
JP2017501205A5 true JP2017501205A5 (enExample) 2018-02-08
JP6759100B2 JP6759100B2 (ja) 2020-09-23

Family

ID=53493998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016544593A Expired - Fee Related JP6759100B2 (ja) 2013-12-30 2014-12-30 治療用阻害化合物

Country Status (11)

Country Link
US (2) US10266515B2 (enExample)
EP (1) EP3089746A4 (enExample)
JP (1) JP6759100B2 (enExample)
KR (1) KR20160106627A (enExample)
CN (1) CN106061480B (enExample)
AU (2) AU2014373735B2 (enExample)
BR (1) BR112016015449A8 (enExample)
CA (1) CA2935683A1 (enExample)
EA (1) EA032713B1 (enExample)
MX (1) MX2016008688A (enExample)
WO (1) WO2015103317A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (zh) 2010-04-22 2015-12-09 弗特克斯药品有限公司 制备环烷基甲酰胺基-吲哚化合物的方法
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
CN106061480B (zh) * 2013-12-30 2020-02-28 莱福斯希医药公司 治疗性抑制性化合物
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
BR112017000816A2 (pt) * 2014-07-16 2017-12-05 Lifesci Pharmaceuticals Inc compostos inibitórios terapêuticos
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3404021A4 (en) 2016-01-12 2019-09-11 Nippon Chemiphar Co., Ltd. VOLTAGE-RELATED T-TYPE CALCIUM CHANNEL INHIBITOR
WO2017207983A1 (en) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
CN107033015B (zh) * 2017-06-02 2019-04-30 南京欧信医药技术有限公司 一种药物中间体的合成方法
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
US11497752B2 (en) 2018-01-30 2022-11-15 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2019166874A1 (en) * 2018-02-28 2019-09-06 Lifesci Pharmaceuticals, Inc. Treatment of hereditary angioedema
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN118373875A (zh) 2018-05-29 2024-07-23 奥默罗斯公司 Masp-2抑制剂和使用方法
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020081588A1 (en) 2018-10-17 2020-04-23 Dana-Farber Cancer Institute, Inc. Swi/snf family chromatin remodeling complexes and uses thereof
WO2020160196A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020160100A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
CN110256342B (zh) * 2019-07-16 2022-06-07 河南省科学院化学研究所有限公司 一种2-氰基喹啉衍生物的合成方法
WO2021028645A1 (en) * 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
WO2021113682A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
WO2021113698A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110531A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
EP4096668A4 (en) * 2020-01-29 2024-02-28 Foghorn Therapeutics Inc. COMPOUNDS AND USES THEREOF
BR112022015004A2 (pt) 2020-01-29 2022-09-20 Foghorn Therapeutics Inc Composto, composição farmacêutica, métodos para diminuir a atividade de um complexo baf, induzir apoptose, reduzir o crescimento tumoral, suprimir a progressão e a colonização metastática do câncer e reduzir o nível e/ou a atividade de brg1 e/ou brm em um câncer e métodos de tratamento e de inibição de brm e brg1
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
JP2024509268A (ja) 2021-03-09 2024-02-29 フォグホーン セラピューティクス インコーポレイテッド 結晶形、それらを含有する組成物、及びそれらの使用方法
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
US12319655B2 (en) 2021-12-09 2025-06-03 Deciphera Pharmaceuticals, Llc RAF kinase inhibitors and methods of use thereof
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
EP4737450A1 (en) * 2023-06-30 2026-05-06 Longwood Pharmaceuticals (Hangzhou) Co., Ltd Heteroaromatic formamide compounds and uses thereof in medicine
WO2025160190A1 (en) * 2024-01-23 2025-07-31 Retune Pharma Inc. Therapeutic inhibitory compounds
WO2025247982A1 (en) * 2024-05-29 2025-12-04 Grünenthal GmbH Piperazines which act as sstr4 modulators

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW212792B (enExample) * 1991-09-13 1993-09-11 Shell Internat Res Schappej B V
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW575562B (en) * 1998-02-19 2004-02-11 Agrevo Uk Ltd Fungicides
ES2225252T3 (es) * 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
ATE447404T1 (de) * 2002-03-29 2009-11-15 Novartis Vaccines & Diagnostic Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
WO2004078114A2 (en) * 2003-02-28 2004-09-16 Encysive Pharmaceuticals Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists.
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
CA2633740A1 (en) * 2005-12-22 2007-06-28 Crystalgenomics, Inc. Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
US20070254894A1 (en) * 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
EP1987004A2 (en) 2006-02-16 2008-11-05 Boehringer Ingelheim International GmbH Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
MY148851A (en) * 2006-12-14 2013-06-14 Bayer Ip Gmbh Dihydropyridine derivatives as useful as protein kinase inhibitors
WO2008098978A2 (en) * 2007-02-16 2008-08-21 Glaxo Group Limited Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
EP2269990A4 (en) 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
US20090270407A1 (en) * 2008-04-25 2009-10-29 E. I. Du Pont De Nemours And Company Fungicidal isoxazolidines
MX2011000460A (es) 2008-07-18 2011-03-15 Takeda Pharmaceutical Derivados de benzazepina y su uso como antagonistas de histamina h3.
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
CN102365278B (zh) * 2009-03-26 2015-05-06 先正达参股股份有限公司 杀虫化合物
GB201004739D0 (en) * 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
HUE037860T2 (hu) * 2010-11-19 2018-09-28 Ligand Pharm Inc Heterociklusos aminok és alkalmazásuk
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
CN102904742B (zh) 2011-07-29 2015-10-07 华为终端有限公司 对可执行节点的操作方法及系统
US20150017156A1 (en) * 2011-09-16 2015-01-15 The Ohio State University Esx-mediated transcription modulators and related methods
US9206128B2 (en) * 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013111108A1 (en) * 2012-01-27 2013-08-01 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013111107A1 (en) 2012-01-27 2013-08-01 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
HRP20171459T1 (hr) 2012-12-07 2017-11-03 F. Hoffmann - La Roche Ag Piridin-2-amidi korisni kao agonisti cb2
BR112015028879B1 (pt) 2013-05-23 2022-12-20 Kalvista Pharmaceuticals Limited Compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CA2920815C (en) 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
US9611252B2 (en) * 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
CN106061480B (zh) * 2013-12-30 2020-02-28 莱福斯希医药公司 治疗性抑制性化合物
BR112017000816A2 (pt) * 2014-07-16 2017-12-05 Lifesci Pharmaceuticals Inc compostos inibitórios terapêuticos
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS

Similar Documents

Publication Publication Date Title
ZA201900694B (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
MX377635B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
JP2016513137A5 (enExample)
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
JP2016530283A5 (enExample)
AR087545A1 (es) 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio
JP2013510124A5 (enExample)
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
IN2014MN02106A (enExample)
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
CR20160527A (es) Derivados de carboxamida
WO2016127168A3 (en) Mebendazole polymorph for treatment and prevention of tumors
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
UY36123A (es) Derivados de carboxamida